company background image
SYNG

Syngene International NSEI:SYNGENE Stock Report

Last Price

₹568.25

Market Cap

₹225.9b

7D

5.4%

1Y

-2.7%

Updated

27 Jun, 2022

Data

Company Financials +
SYNGENE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

SYNGENE Stock Overview

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally.

Rewards

Earnings are forecast to grow 22.56% per year

Risk Analysis

SYNGENE passed our risk checks.

Syngene International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syngene International
Historical stock prices
Current Share Price₹568.25
52 Week High₹700.00
52 Week Low₹510.05
Beta0.68
1 Month Change6.82%
3 Month Change-2.69%
1 Year Change-2.72%
3 Year Change74.04%
5 Year Change140.86%
Change since IPO265.96%

Recent News & Updates

May 10
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

SYNGENEIN Life SciencesIN Market
7D5.4%4.5%4.1%
1Y-2.7%-13.4%-0.02%

Return vs Industry: SYNGENE exceeded the Indian Life Sciences industry which returned -12.1% over the past year.

Return vs Market: SYNGENE underperformed the Indian Market which returned -0.9% over the past year.

Price Volatility

Is SYNGENE's price volatile compared to industry and market?
SYNGENE volatility
SYNGENE Average Weekly Movement5.1%
Life Sciences Industry Average Movement6.5%
Market Average Movement6.9%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.5%

Stable Share Price: SYNGENE is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SYNGENE's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,437Jonathan Hunthttps://www.syngeneintl.com

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services.

Syngene International Fundamentals Summary

How do Syngene International's earnings and revenue compare to its market cap?
SYNGENE fundamental statistics
Market Cap₹225.89b
Earnings (TTM)₹3.96b
Revenue (TTM)₹26.04b

57.1x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYNGENE income statement (TTM)
Revenue₹26.04b
Cost of Revenue₹7.49b
Gross Profit₹18.55b
Other Expenses₹14.59b
Earnings₹3.96b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)9.97
Gross Margin71.24%
Net Profit Margin15.20%
Debt/Equity Ratio23.9%

How did SYNGENE perform over the long term?

See historical performance and comparison

Dividends

0.09%

Current Dividend Yield

5%

Payout Ratio

Does SYNGENE pay a reliable dividends?

See SYNGENE dividend history and benchmarks
When do you need to buy SYNGENE by to receive an upcoming dividend?
Syngene International dividend dates
Ex Dividend DateJun 30 2022
Dividend Pay DateAug 19 2022
Days until Ex dividend2 days
Days until Dividend pay date52 days

Does SYNGENE pay a reliable dividends?

See SYNGENE dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is SYNGENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNGENE?

Other financial metrics that can be useful for relative valuation.

SYNGENE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.6x
Enterprise Value/EBITDA30.1x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does SYNGENE's PE Ratio compare to its peers?

SYNGENE PE Ratio vs Peers
The above table shows the PE ratio for SYNGENE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average47.7x
DIVISLAB Divi's Laboratories
32.9x2.8%₹975.2b
TARSONS Tarsons Products
36.8x17.4%₹37.0b
540701 Dishman Carbogen Amcis
102.5x75.0%₹18.5b
524394 Vimta Labs
18.6xn/a₹7.7b
SYNGENE Syngene International
57.1x22.6%₹225.9b

Price-To-Earnings vs Peers: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the peer average (47.7x).


Price to Earnings Ratio vs Industry

How does SYNGENE's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

Price-To-Earnings vs Industry: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the Indian Life Sciences industry average (33x)


Price to Earnings Ratio vs Fair Ratio

What is SYNGENE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNGENE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio57.1x
Fair PE Ratio29.5x

Price-To-Earnings vs Fair Ratio: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).


Share Price vs Fair Value

What is the Fair Price of SYNGENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYNGENE (₹568.25) is trading above our estimate of fair value (₹249.78)

Significantly Below Fair Value: SYNGENE is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: SYNGENE is poor value based on its PEG Ratio (2.5x)


Discover undervalued companies

Future Growth

How is Syngene International forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


22.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYNGENE's forecast earnings growth (22.6% per year) is above the savings rate (6.7%).

Earnings vs Market: SYNGENE's earnings (22.6% per year) are forecast to grow faster than the Indian market (17.4% per year).

High Growth Earnings: SYNGENE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SYNGENE's revenue (16% per year) is forecast to grow faster than the Indian market (11.5% per year).

High Growth Revenue: SYNGENE's revenue (16% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SYNGENE's Return on Equity is forecast to be low in 3 years time (16.3%).


Discover growth companies

Past Performance

How has Syngene International performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


8.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SYNGENE has high quality earnings.

Growing Profit Margin: SYNGENE's current net profit margins (15.2%) are lower than last year (18.5%).


Past Earnings Growth Analysis

Earnings Trend: SYNGENE's earnings have grown by 8% per year over the past 5 years.

Accelerating Growth: SYNGENE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SYNGENE had negative earnings growth (-2.2%) over the past year, making it difficult to compare to the Life Sciences industry average (47.7%).


Return on Equity

High ROE: SYNGENE's Return on Equity (12%) is considered low.


Discover strong past performing companies

Financial Health

How is Syngene International's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SYNGENE's short term assets (₹22.1B) exceed its short term liabilities (₹12.3B).

Long Term Liabilities: SYNGENE's short term assets (₹22.1B) exceed its long term liabilities (₹10.4B).


Debt to Equity History and Analysis

Debt Level: SYNGENE has more cash than its total debt.

Reducing Debt: SYNGENE's debt to equity ratio has reduced from 58.9% to 23.9% over the past 5 years.

Debt Coverage: SYNGENE's debt is well covered by operating cash flow (73.5%).

Interest Coverage: SYNGENE's interest payments on its debt are well covered by EBIT (17.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Syngene International current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.087%

Current Dividend Yield

Upcoming Dividend Payment

TodayJun 28 2022Ex Dividend DateJun 30 2022Dividend Pay DateAug 19 202250 days from Ex DividendBuy in the next 2 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: SYNGENE's dividend (0.087%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.43%).

High Dividend: SYNGENE's dividend (0.087%) is low compared to the top 25% of dividend payers in the Indian market (1.89%).


Stability and Growth of Payments

Stable Dividend: SYNGENE is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: SYNGENE is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: SYNGENE is not paying a notable dividend for the Indian market.


Cash Payout to Shareholders

Cash Flow Coverage: SYNGENE is not paying a notable dividend for the Indian market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Jonathan Hunt (52 yo)

6.42yrs

Tenure

₹65,170,000

Compensation

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...


CEO Compensation Analysis

Compensation vs Market: Jonathan's total compensation ($USD832.63K) is about average for companies of similar size in the Indian market ($USD642.44K).

Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SYNGENE's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: SYNGENE's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SYNGENE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Syngene International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Syngene International Limited
  • Ticker: SYNGENE
  • Exchange: NSEI
  • Founded: 1993
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹225.893b
  • Shares outstanding: 397.17m
  • Website: https://www.syngeneintl.com

Number of Employees


Location

  • Syngene International Limited
  • Biocon SEZ, Biocon Park,
  • Plot No. 2 & 3
  • Bengaluru
  • Karnataka
  • 560099
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.